IQVIA Holdings Inc. logo
IQVIA Holdings Inc. (IQV)
Compare

IQVIA Holdings Inc. (IQV) PB Ratio: 4.93

popular:market cap|pe ratio|revenue|price history|total return

Is IQVIA Holdings Inc.’s P/B ratio high or low?

IQVIA Holdings Inc.'s P/B ratio of 4.93 is 26% below its 5-year average of 6.64, near the low end of its 5-year range (4.07–9.47).

8.79% below its 12-month average of 5.41.

P/E Ratio|ROE|Debt to Equity|All Metrics

IQV PB Ratio Chart

IQV PB Ratio
4.93+4.67% 1Y
Zoom

IQV Average PB Ratio Chart

IQV Current vs Average PB Ratio Chart

IQV PB Ratio Metrics

PB RATIO

4.93

PB RATIO AVG TTM

5.41

PB RATIO AVG 3Y

5.98

PB RATIO AVG 5Y

6.64

PB RATIO AVG 10Y

5.48

PB RATIO AVG 15Y

5.48

PB RATIO AVG 20Y

5.48

CURRENT VS TTM AVG

-8.79%

CURRENT VS 3Y AVG

-17.59%

CURRENT VS 5Y AVG

-25.72%

CURRENT VS 10Y AVG

-10.07%

CURRENT VS 15Y AVG

-10.07%

CURRENT VS 20Y AVG

-10.07%

IQV Competitors' PB Ratio

NAMEMARKET CAPPB RATIOTTM3Y5Y
IQVIA Holdings Inc. (IQV)$30.08B4.935.415.986.64
Medline Inc. (MDLN)$30.90B2.673.193.193.19
Biogen Inc. (BIIB)$28.94B1.551.341.772.39
DexCom, Inc. (DXCM)$28.92B9.9810.8916.2818.92
Centene Corporation (CNC)$32.26B1.510.871.211.41
Veeva Systems Inc. (VEEV)$26.31B3.725.846.759.02
Zoetis Inc. (ZTS)$34.27B10.6812.9615.2216.73
Agilent Technologies, Inc. (A)$36.21B5.255.576.126.99
Waters Corporation (WAT)$23.21B1.958.2813.9232.36
Mettler-Toledo International Inc. (MTD)$22.82BN/A1966.63623.56375.27

P/B vs. its own history

At 4.93, P/B is in its normal range, sitting higher than 40% of its 9-year history.

9-year low

2.11

median

5.54

9-year high

9.47

cheaperricher

Book Value Analysis

P/B Ratio

4.93

Market Price / Book Value per Share

IQVIA Holdings Inc. PB Ratio Formula & Definition

PB Ratio = Market Cap / Total Shareholders' Equity

The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

IQVIA Holdings Inc. PB Ratio FAQ

What is the P/B ratio for IQVIA Holdings Inc. (IQV)?
The P/B ratio for IQV stock is 4.93.
Is IQVIA Holdings Inc.'s P/B ratio high or low?
IQVIA Holdings Inc.'s P/B ratio of 4.93 is 26% below its 5-year average of 6.64, near the low end of its 5-year range (4.07–9.47).
What is the TTM average P/B ratio for IQVIA Holdings Inc. (IQV)?
The TTM average P/B ratio for IQV stock is 5.41.
What is the 3Y average P/B ratio for IQVIA Holdings Inc. (IQV)?
The 3Y average P/B ratio for IQV stock is 5.98.
What is the 5Y average P/B ratio for IQVIA Holdings Inc. (IQV)?
The 5Y average P/B ratio for IQV stock is 6.64.
What is the 10Y average P/B ratio for IQVIA Holdings Inc. (IQV)?
The 10Y average P/B ratio for IQV stock is 5.48.
What is the 15Y average P/B ratio for IQVIA Holdings Inc. (IQV)?
The 15Y average P/B ratio for IQV stock is 5.48.
What is the 20Y average P/B ratio for IQVIA Holdings Inc. (IQV)?
The 20Y average P/B ratio for IQV stock is 5.48.

IQVIA Holdings Inc. PB Ratio History

DATEPB RATIO
2026-06-114.93
2026-06-104.97
2026-06-095.08
2026-06-085.01
2026-06-055.01
2026-06-045.10
2026-06-034.97
2026-06-024.93
2026-06-015.10
2026-05-294.97
2026-05-284.94
2026-05-274.52
2026-05-264.42
2026-05-224.58
2026-05-214.59
2026-05-204.68
2026-05-194.73
2026-05-184.72
2026-05-154.62
2026-05-144.66
2026-05-134.71
2026-05-124.78
2026-05-114.74
2026-05-084.88
2026-05-074.88
2026-05-064.82
2026-05-054.82
2026-05-044.25
2026-05-014.17
2026-04-304.19
2026-04-294.14
2026-04-284.20
2026-04-274.33
2026-04-244.29
2026-04-234.25
2026-04-224.63
2026-04-214.64
2026-04-204.67
2026-04-174.66
2026-04-164.55
2026-04-154.71
2026-04-144.63
2026-04-134.55
2026-04-104.42
2026-04-094.47
2026-04-084.56
2026-04-074.51
2026-04-064.51
2026-04-024.58
2026-04-014.56
2026-03-314.51
2026-03-304.39
2026-03-274.33
2026-03-264.48
2026-03-254.38
2026-03-244.39
2026-03-234.41
2026-03-204.39
2026-03-194.40
2026-03-184.41
2026-03-174.45
2026-03-164.36
2026-03-134.35
2026-03-124.31
2026-03-114.54
2026-03-104.52
2026-03-094.72
2026-03-064.61
2026-03-054.72
2026-03-044.70
2026-03-034.60
2026-03-024.61
2026-02-274.73
2026-02-264.51
2026-02-254.28
2026-02-244.36
2026-02-234.29
2026-02-204.38
2026-02-194.48
2026-02-184.52
2026-02-174.35
2026-02-134.65
2026-02-124.71
2026-02-114.94
2026-02-105.09
2026-02-095.37
2026-02-065.23
2026-02-055.04
2026-02-045.65
2026-02-035.68
2026-02-026.45
2026-01-306.42
2026-01-296.57
2026-01-286.68
2026-01-276.72
2026-01-266.67
2026-01-236.56
2026-01-226.66
2026-01-216.73
2026-01-206.51
2026-01-166.62
2026-01-156.73
2026-01-146.73
2026-01-136.73
2026-01-126.71
2026-01-096.76
2026-01-086.78
2026-01-076.81
2026-01-066.70
2026-01-056.54
2026-01-026.28
2025-12-316.28
2025-12-306.35
2025-12-296.33
2025-12-266.33
2025-12-246.30
2025-12-236.28
2025-12-226.25
2025-12-196.15
2025-12-186.20
2025-12-176.17
2025-12-166.18
2025-12-156.23
2025-12-126.20
2025-12-116.30
2025-12-106.21
2025-12-096.08
2025-12-086.23
2025-12-056.30
2025-12-046.27
2025-12-036.33
2025-12-026.29
2025-12-016.37
2025-11-286.41
2025-11-266.46
2025-11-256.46
2025-11-246.36
2025-11-216.27
2025-11-206.05
2025-11-196.06
2025-11-186.06
2025-11-176.02
2025-11-146.15
2025-11-136.23
2025-11-126.16
2025-11-116.09
2025-11-105.94
2025-11-075.87
2025-11-065.88
2025-11-055.86
2025-11-045.88
2025-11-035.96
2025-10-316.03
2025-10-306.03
2025-10-296.07
2025-10-286.08
2025-10-276.52
2025-10-246.61
2025-10-236.59
2025-10-226.53
2025-10-216.55
2025-10-206.36
2025-10-176.13
2025-10-166.17
2025-10-156.09
2025-10-146.14
2025-10-136.11
2025-10-105.94
2025-10-096.09
2025-10-086.01
2025-10-076.02
2025-10-066.15
2025-10-036.19
2025-10-026.13
2025-10-016.11
2025-09-305.69
2025-09-295.42
2025-09-265.38
2025-09-255.30
2025-09-245.43
2025-09-235.59
2025-09-225.63
2025-09-195.61
2025-09-185.70
2025-09-175.60
2025-09-165.60
2025-09-155.57
2025-09-125.61
2025-09-115.72
2025-09-105.51
2025-09-095.68
2025-09-085.63
2025-09-055.63
2025-09-045.52
2025-09-035.53
2025-09-025.51
2025-08-295.72
2025-08-285.66
2025-08-275.66
2025-08-265.63
2025-08-255.64
2025-08-225.73
2025-08-215.56
2025-08-205.76
2025-08-195.77
2025-08-185.77
2025-08-155.73
2025-08-145.68
2025-08-135.70
2025-08-125.57
2025-08-115.40
2025-08-085.39
2025-08-075.36
2025-08-065.32
2025-08-055.51
2025-08-045.48
2025-08-015.47
2025-07-315.57
2025-07-305.74
2025-07-295.83
2025-07-285.93
2025-07-255.97
2025-07-246.02
2025-07-235.82
2025-07-225.62
2025-07-214.72
2025-07-184.77
2025-07-174.85
2025-07-164.71
2025-07-154.68
2025-07-144.75
2025-07-114.83
2025-07-104.91
2025-07-094.81
2025-07-084.88
2025-07-074.82
2025-07-034.87
2025-07-024.89
2025-07-014.83
2025-06-304.68
2025-06-274.67
2025-06-264.69
2025-06-254.71
2025-06-244.71
2025-06-234.61
2025-06-204.59
2025-06-184.59
2025-06-174.57
2025-06-164.73
2025-06-134.66
2025-06-124.72
2025-06-114.71
2025-06-104.74
2025-06-094.58
2025-06-064.52
2025-06-054.37
2025-06-044.39
2025-06-034.24
2025-06-024.13
2025-05-304.17

Showing the most recent 260 of 2,342 data points. The chart above shows the full history.

Related Metrics

P/E RatioROEDebt to EquityAll Metrics

About IQVIA Holdings Inc.

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Durham, NC
89,000 employees
www.iqvia.com
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ari Bousbib
View full financials